June 24, 2022 – Utrecht, the Netherlands Cresco Spine, a new player in the spinal arena and a spin-off of the University Medical Center Utrecht (the Netherlands), today announced that it raised seed investments from InSpine and Utrecht Health Seed Fund (UHSF) to continue its development of their unique surgical spinal correction platform “Dynamic Implant […]
This author has yet to write their bio.
Meanwhile lets just say that we are proud anoukd@gel3t contributed a whooping 12 entries.
Our portfolio company Targed Biopharmaceuticals raised Series A financing of € 39 million to develop improved treatments for thrombotic diseases. The financing was co-led by Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures, and joined by existing investors First, Curie Capital and UHSF. Congratulations to the whole TargED team! Please […]
Before we knew, we’re celebrating Utrecht Health Seed Fund’s first anniversary! And what a year it has been. We can’t express how proud we are of our exceptional portfolio companies and the talented entrepreneurs and scientists driving these ventures: – TargED Biopharmaceuticals is developing a next generation clot-busting drug with unique properties, focusing on Acute […]
We are delighted with the new investment in SentryX, a next generation, innovative pain relief therapy platform, focusing on orthopedic surgical post-procedural pain. Press release: June 9, 2021 – Utrecht, the Netherlands SentryX, a spin-off of the University Medical Center Utrecht (the Netherlands) today announced that it raised €3.2M in seed funding for the development of their […]
TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, today announced the appointment of Ludo Haazen as Chief Medical Officer (CMO). Kristof Vercruysse, CEO of TargED commented: “We are delighted that Ludo is joining our team as CMO. In Ludo, we found the ideal candidate to support the company’s transition from preclinical to […]
We’re excited to be investing in NTrans Technologies BV, a gene editing therapy company focusing on Duchenne Muscular Dystrophy, together with Essential Ventures, BOP Capital and Starfish Innovations. May 27, 2021 Utrecht, The Netherlands – NTrans Technologies (NTrans), a leader in gene editing technologies, today announced a Series A investment of 2 million Euros, led […]
- Cresco Spine closes seed investments to develop innovative dynamic surgical therapy for scoliosis27/06/2022 - 11:18
- TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients22/02/2022 - 09:52
- Utrecht Health Seed Fund’s first anniversary!03/09/2021 - 12:42
UTRECHT HEALTH SEED FUND
3584 CM Utrecht
Visiting address: Yalelaan 62, Utrecht
Website: Consortius Wetenschapscommunicatie